Olainfarm Announces €100m Investment For Ten Products Every Year
In A Bid To Be Among Top Ten Firms In Central And Eastern Europe
Olainfarm has announced plans to find €100m in funding – including through increased efficiencies and reinvestment of profits – to invest in a five-year plan that will see it develop ten new products each year as part of efforts to become one of the top ten pharma players in Central and Eastern Europe.
You may also be interested in...
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.
US-based Phlow and Fresenius Kabi have announced an alliance to supply essential medicines, including injectables, for public health emergencies and to Children’s Hospital Coalition, a project by Phlow. In an exclusive interview with Generics Bulletin, Phlow chief business officer Dan Hackman talks about the partnership, addressing US supply chain disruptions, domestic manufacturing and more.
The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.